tradingkey.logo

BRIEF-Tivic Health Acquires Exclusive Worldwide Rights To Phase III TLR5 Agonist

ReutersFeb 12, 2025 1:34 PM

- Tivic Health Systems TIVC.O:

  • TIVIC HEALTH ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO PHASE III TLR5 AGONIST FROM STATERA BIOPHARMA

  • TIVIC HEALTH SYSTEMS INC - TO PAY STATERA $1.2 MILLION IN EQUITY AND $300,000 CASH FOR ENTOLIMOD

Source text: ID:nBw6pThY2a

Further company coverage: TIVC.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI